CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness.

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Aberrant CXCR4 signaling is linked to lymphoma development, progression, and treatment resistance.
• CXCR4 plays a role in various cellular processes, including lymphocyte development and activation.

Purpose of the Study:

• To investigate the role of CXCR4 hyperactivation in lymphoma pathogenesis using a gain-of-function mouse model.
• To identify the specific oncogenic pathways and cellular mechanisms affected by CXCR4 hyperactivation in B cells.

Main Methods:

• Utilized a mouse model with a CXCR4 gain-of-function mutation (CXCR4^C1013G).
• Analyzed B cell populations, disease onset, and phenotype in murine chronic lymphocytic leukemia (CLL) and aggressive B-cell lymphoma models.
• Investigated transcriptional programs, including PLK1/FOXM1 and MYC pathways, in B cells with hyperactivated CXCR4 signaling.

Main Results:

• CXCR4 hyperactivation led to expansion of transitional B1 lymphocytes, precursors to CLL.
• Accelerated disease onset and more aggressive phenotype observed in the Eµ-TCL1 CLL model with CXCR4 hyperactivation.
• Hyperactivated CXCR4 signaling cooperated with TCL1 to induce a distinct oncogenic transcriptional program in B cells, enriched for Richter's syndrome signatures.
• MYC activation in aggressive lymphoma correlated with increased CXCR4 expression.

Conclusions:

• CXCR4 hyperactivation acts as a co-driver in aggressive lymphoma.
• CXCR4 signaling is a crucial activator of key oncogenic pathways in B cells.
• Targeting CXCR4 may offer therapeutic strategies for aggressive B-cell lymphomas and CLL.